查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2034867

全球多特異性抗體市場：市場規模、抗體銷售、劑量、專利、定價、專有技術和臨床試驗洞察（2031 年）

Global Multispecific Antibodies Market Size, Antibodies Sales, Dosage, Patent, Price, Proprietary Technologies & Clinical Trials Insight 2031
出版日期: | 出版商: KuicK Research | 英文 1200 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球多特異性抗體市場－市場規模、抗體銷售、劑量、專利、定價、專有技術和臨床試驗洞察（2031 年）報告的主要發現和亮點：

  • 全球多特異性抗體市場機會：到2031年將達600億美元
  • 全球多特異性抗體市場成長（2020-2025）：複合年成長率約40%，絕對成長率為430%。
  • 深入了解已通過核准的多特異性抗體的劑量、專利、定價和銷售情況。
  • 全球、區域、年度和季度收入洞察：2020 年至 2026 年第一季
  • 按公司、適應症和階段分類的多特異性抗體臨床試驗概況。
  • 目前有超過750種多特異性抗體正在進行臨床試驗。
  • 對雙特異性、三重複和四重複抗體的臨床試驗和銷售情況的深入了解
  • 競爭格局

多特異性抗體的必要性及本報告的意義

從標準的雙特異性抗體到新一代的三特異性和四特異性抗體，多特異性抗體正在迅速改變我們治療疾病的方式。它們能夠針對多個生物標的，使得這種新方法能夠有效應對腫瘤異質性、免疫逃脫和冗餘訊號通路等疾病複雜性。鑑於目前基於單一或兩個生物標的標靶的治療方法仍面臨諸多挑戰，多特異性抗體可望為藥物研發帶來新的突破。

鑑於雙特異性抗體研發的日益成功，更先進、更有效的藥物發現和開發正迎來新的機會。透過將不同的作用機制整合到單一治療藥物中，有望顯著改善多種疾病的治療效果。尤其是在癌症治療領域，將免疫刺激或免疫調節與腫瘤標靶化結合，可能為現有的治療模式提供更有效的解決方案。

本報告旨在對免疫治療抗體領域這一新興的細分市場進行前瞻性分析。具體而言，本報告並非著重介紹該技術的基本事實，而是旨在突出創新領域、挑戰以及先進治療方法研發中不斷變化的競爭格局。

過去十年間，Kuick 本公司率先發布報告，分析全球雙特異性抗體、三重抗體和四重抗體市場。這主要得益於這些分子研發帶來的未來成長機遇，它們有望成為下一代藥物的主要驅動力之一。

報告中包含對臨床試驗的深入分析

臨床開發已成為決定多特異性抗體成敗的關鍵因素。儘管目前市面上的多特異性抗體數量仍然相對較少，但許多分子正在進行臨床試驗，主要集中在腫瘤學和免疫學領域。

本報告深入分析了從早期到III期臨床試驗的現況。報告分析了研發人員如何應對臨床開發中的關鍵挑戰，例如劑量問題、安全性問題以及如何利用生物標記篩選合適的患者。報告尤其關注復發或難治性患者的臨床試驗，在這些試驗中，多特異性抗體必須展現臨床優勢。

本報告從多個觀點對這些試驗進行了檢驗，包括適應症、聯合治療、地理分佈和分層情況。透過從作用機制、試驗設計和標靶選擇的角度分析這些試驗，本報告可以深入了解新治療方法研發的成功可能性和發展趨勢。

專注於多特異性抗體研發的主要企業

多特異性抗體領域的競爭格局由老牌製藥巨頭和前沿生物技術公司共同主導。羅氏、安進和強生等大型製藥企業正利用其在研發、臨床試驗和商業化方面的經驗，進軍更先進的多特異性抗體領域，從而有助於市場的穩定和確定性。

此外，我們看到新興生物技術公司正利用獨特的平台技術和新型分子結構來推動創新，這已成為一種趨勢。 Zymeworks、Alligator Bioscience 和 ABL Bio 就是這類創新公司的典範。這些公司反應迅速，其技術優勢使其成為優秀的合作夥伴和潛在的收購目標。

技術平台、合作夥伴關係和協議

超越雙特異性策略在穩定性、生產和安全性方面都帶來了挑戰，因此技術創新對於多特異性抗體的進一步開發至關重要。專有技術平台能夠開發出具有更高特異性和生產效率的抗體。例如，QLSF Biotherapeutics 開發了 TECAD（T 細胞共刺激親和力驅動工程）平台，用於設計高特異性分子；而安進公司則持續利用其 BiTE 平台改進新的抗體工程製程。

合作與併購在推動多特異性抗體領域的創新方面也發揮著至關重要的作用。例如，勃林格殷格翰與先聲藥業的合作，以及Genmab於2025年12月收購Merus，都顯示了製藥公司如何在分散風險的同時獲得尖端平台。

本報告分析了部分合作、合併和授權協議，揭示了這些交易的結構以及它們對未來商業趨勢的啟示。

一份概述多特異性抗體片段未來發展方向的報告。

多特異性抗體的前景極為光明，這得益於資金籌措的增加、研發管線的推進以及持續的創新。隨著越來越多的候選藥物進入研發的最後階段，未來幾年獲得監管部門核准的可能性似乎越來越高。

多特異性抗體的聯合應用預計將在該領域，尤其是在腫瘤學領域，日益受到重視。開發用於聯合治療的多特異性抗體已成為一種普遍做法，既可作為核心治療，也可作為現有療法的輔助性治療。此外，多特異性抗體在自體免疫疾病和發炎性疾病治療的應用也在不斷擴展。

對於關注該領域的投資者而言，了解創新、發展進展和市場定位至關重要。本報告精心挑選了有關這些要素的信息，旨在幫助投資者做出明智的決策。

目錄

第1章：調查方法

第2章：下一代多特異性抗體簡介

第3章：下一代多特異性抗體：當前臨床開發和未來商業化前景

  • 當前市場概況
  • 未來商業化機遇
  • 下一代多特異性抗體專有技術（公司名稱）

第4章：下一代多特異性抗體的臨床趨勢（按適應症分類）

  • 癌症
  • 血液疾病
  • 微生物感染疾病
  • 自體免疫疾病與發炎性疾病
  • 眼科疾病

第5章：下一代多特異性抗體的臨床開發與區域市場趨勢

  • 美國
  • 歐洲
  • 中國
  • 英國
  • 日本
  • 澳洲
  • 韓國
  • 加拿大

第6章：核准的多特異性抗體－臨床概述、定價、劑量和銷售趨勢

  • 概述
  • 臨床概述、定價和劑量資訊。
  • 銷售趨勢分析（2020年-2026年第一季）

第7章 多特異性抗體全球臨床試驗概述

第8章 雙特異性抗體的臨床試驗（依公司、適應症和階段分類）

  • 研究
  • 臨床前
  • 第一階段
  • 第一/二期
  • 第二階段
  • 第二/三期
  • 第三階段
  • 預註冊
  • 掛號的

第9章：市售雙特異性抗體的臨床研究結果（依公司、國家及適應症分類）

第10章：全球三特異性抗體臨床試驗概況（依公司、國家、適應症和階段分類）

  • 研究
  • 臨床前
  • 第一階段
  • 第一/二期
  • 第二階段
  • 第二/三期

第11章：按公司、國家、適應症和階段分類的四特異性抗體臨床試驗概況

  • 臨床前
  • 第一階段
  • 第一/二期
  • 第二階段

第12章 競爭格局

  • AbbVie
  • ABL Bio
  • Abzyme Therapeutics
  • Affimed Therapeutics
  • Akeso Biopharma
  • Alligator Bioscience
  • Amgen
  • APITBIO
  • Astellas Pharma
  • AstraZeneca
  • Aptevo Therapeutics
  • BioAtla
  • Biocytogen Pharmaceuticals
  • Biosion
  • CStone Pharmaceuticals
  • Diagonal Therapeutics
  • EpimAb Biotherapeutics
  • FutureGen Biopharmaceutical
  • Genentech
  • Genmab
  • Genor Biopharma
  • Gensun Biopharma
  • Harbour BioMed
  • IGM Biosciences
  • I-MAB Biopharma
  • ImmuneOnco Biopharma
  • ImmunoPrecise Antibodies
  • Innate Pharma
  • Innovent Biologics
  • Invenra
  • Johnson & Johnson
  • Kenjockety Biotechnology
  • LaNova Medicines Limited
  • Light Chain Bioscience
  • Linton Pharm
  • Lyvgen Biopharma
  • MacroGenics
  • Merck
  • Merus
  • ModeX Therapeutics (OPKO Health)
  • Molecular Partners
  • NovaRock Biotherapeutics
  • Numab
  • OPKO Health
  • Pfizer
  • Regeneron Pharmaceuticals
  • Revitope
  • Roche
  • Sanofi
  • Sichuan Baili Pharmaceutical
  • SystImmune
  • Virtuoso Therapeutics
  • Xencor
  • Y-Biologics
  • Zymeworks
簡介目錄

Global Multispecific Antibodies Market Size, Antibodies Sales, Dosage, Patent, Price, Proprietary Technologies & Clinical Trials Insight 2031 Report Findings & Highlights:

  • Global Multispecific Antibodies Market Opportunity: USD 60 Billion By 2031
  • Global Multispecific Antibodies Market Growth 2020 - 2025: Around 40% CAGR & 430% Absolute Growth
  • Approved Multispecific Antibodies Dosage, Patent, Price & Sales Insight
  • Global, Regional, Annual, Quarterly Sales Insight: 2020 Till Q1'2026
  • Multispecific Antibodies Clinical Trials Insight By Company, Indication & Phase
  • Multispecific Antibodies In Clinical Trials: > 750 Antibodies
  • Bispecific, Trispecific & Tetraspecific Antibodies Clinical Trials & Sales Insight
  • Competitive Landscape

Need For Multispecific Antibodies & Why This Report?

Multispecific antibodies, extending from standard bispecifics to the next generation of trispecific and tetraspecific antibodies, are quickly revolutionizing the therapeutic landscape. Through the ability to target multiple biological entities, this new approach can effectively address disease complexities such as tumor heterogeneity, immune evasion, and redundant signaling pathways. As current treatments based on a single biological target or even two targets continue to show challenges, multispecific antibodies could offer the next level of success in drug development.

In light of the increasing successes in developing bispecific antibodies, new opportunities arise for even more advanced and effective drug discovery and development. The inclusion of different mechanisms within a single therapeutic drug can lead to significant improvements in treating various diseases. In cancer, importantly, combining immune stimulation or immune modulation with tumor targeting can result in a more effective solution to existing treatment paradigms.

This report aims at offering a forward looking analysis of the new segment in the field of immunotherapeutic antibodies. In this case, rather than providing basic facts about this technology, the report is intended to show the areas of innovation, challenges, and the evolving competitive landscape in the development of advanced therapies.

We, at Kuick Research, have been one of the pioneers publishing reports dedicated to analyzing the global market for bispecific, trispecific, and tetraspecific antibodies over the last decade. The reason behind this lies in the considerable future market growth opportunity associated with the development of such molecules, which are expected to become one of the main drivers for next generation drugs.

Clinical Trials Insight Included In Report

Clinical development emerges as a crucial parameter for shaping the fate of multispecific antibodies. Although the current number of marketed multispecific antibodies is still relatively small, an impressive pipeline of molecules advances further in clinical trials - mostly in oncology and immunology indications.

The report delivers analytical insights about the clinical trial landscape, ranging from early phase trials to pivotal ones. It analyzes how the developers handle major difficulties associated with clinical development including dosing issues, safety concerns, and the use of biomarkers to select the right patients. In particular, special attention is paid to trials conducted in relapsed/refractory populations, wherein multispecific antibodies have to prove their clinical advantage.

These trials are examined in a variety of perspectives, such as the indication, the combination process, geographical spread, and stratification. Through an analysis of these trials in regard to their mechanism, trial design, and selection of targets, the report is able to give an indication on the likelihood of success and the development of new therapies.

Major Companies Active In R&D Of Multispecific Antibodies

The competitive environment in multispecific antibody space is dominated by both well-known pharmaceutical giants and cutting-edge biotech players. Big pharmaceutical firms like Roche, Amgen, and Johnson & Johnson capitalize on their experience in research and development, clinical trials, and commercialization to venture into more sophisticated multispecific antibody spaces, contributing to stability and certainty within the market.

Additionally, there is a rising trend of new biotech firms that innovate using their own platform technologies and new molecular structures. These innovative firms include Zymeworks, Alligator Bioscience, and ABL Bio. They are agile and their technological differentiators make them good collaboration partners and potential acquisition targets.

Technology Platforms, Collaborations & Agreements

Technological innovation plays an important role in pushing multispecific antibodies further since going beyond the bispecific approach brings with it difficulties related to stability, production, and safety. Proprietary technology platforms allow for developing antibodies with higher specificity and manufacturing efficiency. For example, QLSF Biotherapeutics has developed the TECAD (T Cell Engager with Co-Stimulation, Avidity Driven) platform for designing sophisticated multispecific molecules, while Amgen continues refining new antibody engineering processes using its BiTE platform.

Alliances and mergers are no less significant in advancing innovations in the multispecific antibody landscape. Such examples as collaboration between Boehringer Ingelheim and Simcere Pharmaceutical Group or Genmab acquiring Merus in December 2025 demonstrate how pharmaceutical companies can gain access to cutting-edge platforms while distributing risks.

In this report, we will analyze selected alliances, mergers, and licensing arrangements to show how deals are organized and what they say about future business trends.

Report Indicating Future Direction Of Multispecific Antibody Segment

The prospects for multispecific antibodies look extremely positive, backed by increased funding, pipeline developments, and ongoing innovations. With an ever-growing number of candidates progressing into advanced stages of development, the probability of obtaining regulatory approval in the coming years seems increasingly likely.

Multispecific antibody combinations are poised to make a name for themselves in this field moving forward, especially within oncology. The development of multispecific antibodies that can be used as part of combination therapies is becoming increasingly common, both as backbone treatment or as adjuvant to current treatments. There is also growth in the use of multispecific antibodies in autoimmune and inflammatory indications.

For investors interested in this sector, knowledge of innovation, development progress and positioning will prove crucial in making decisions. This report provides a curated view of these factors, enabling informed decision making.

Table of Contents

1. Research Methodology

2. Introduction to Next Generation Multispecific Antibodies

3. Next Generation Multispecific Antibody Current Clinical Development & Future Commercialization Outlook

  • 3.1 Current Market Overview
  • 3.2 Future Commercialization Opportunity
  • 3.3 Next Generation Multispecific Antibody Proprietary Technologies By Company

4. Next Generation Multispecific Antibody Clinical Trends by Indication

  • 4.1 Cancer
  • 4.2 Hematological Disorders
  • 4.3 Microbial Infections
  • 4.4 Autoimmune & Inflammatory Disorders
  • 4.5 Ocular Diseases

5. Next Generation Multispecific Antibody Clinical Development & Market Trends by Region

  • 5.1 US
  • 5.2 Europe
  • 5.3 China
  • 5.4 UK
  • 5.5 Japan
  • 5.6 Australia
  • 5.7 South Korea
  • 5.8 Canada

6. Approved Multispecific Antibodies - Clinical Overview, Pricing, Dosing & Sales Insight

  • 6.1 Overview
  • 6.2 Clinical Overview, Pricing & Dosage Insight
  • 6.3 Sales Insight (2020 - Q1'2026)

7. Global Multispecific Antibodies Clinical Trials Overview

8. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase

  • 8.1 Research
  • 8.2 Preclinical
  • 8.3 Phase I
  • 8.4 Phase I/II
  • 8.5 Phase II
  • 8.6 Phase-II/III
  • 8.7 Phase III
  • 8.8 Preregistration
  • 8.9 Registered

9. Marketed Bispecific Antibodies Clinical Insight By Company, Country & Indication

10. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

  • 10.1 Research
  • 10.2 Preclinical
  • 10.3 Phase I
  • 10.4 Phase I/II
  • 10.5 Phase II
  • 10.6 Phase II/III

11. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase

  • 11.1 Preclinical
  • 11.2 Phase I
  • 11.3 Phase I/II
  • 11.4 Phase II

12. Competitive Landscape

  • 12.1 AbbVie
  • 12.2 ABL Bio
  • 12.3 Abzyme Therapeutics
  • 12.4 Affimed Therapeutics
  • 12.5 Akeso Biopharma
  • 12.6 Alligator Bioscience
  • 12.7 Amgen
  • 12.8 APITBIO
  • 12.9 Astellas Pharma
  • 12.10 AstraZeneca
  • 12.11 Aptevo Therapeutics
  • 12.12 BioAtla
  • 12.13 Biocytogen Pharmaceuticals
  • 12.14 Biosion
  • 12.15 CStone Pharmaceuticals
  • 12.16 Diagonal Therapeutics
  • 12.17 EpimAb Biotherapeutics
  • 12.18 FutureGen Biopharmaceutical
  • 12.19 Genentech
  • 12.20 Genmab
  • 12.21 Genor Biopharma
  • 12.22 Gensun Biopharma
  • 12.23 Harbour BioMed
  • 12.24 IGM Biosciences
  • 12.25 I-MAB Biopharma
  • 12.26 ImmuneOnco Biopharma
  • 12.27 ImmunoPrecise Antibodies
  • 12.28 Innate Pharma
  • 12.29 Innovent Biologics
  • 12.30 Invenra
  • 12.31 Johnson & Johnson
  • 12.32 Kenjockety Biotechnology
  • 12.33 LaNova Medicines Limited
  • 12.34 Light Chain Bioscience
  • 12.35 Linton Pharm
  • 12.36 Lyvgen Biopharma
  • 12.37 MacroGenics
  • 12.38 Merck
  • 12.39 Merus
  • 12.40 ModeX Therapeutics (OPKO Health)
  • 12.41 Molecular Partners
  • 12.42 NovaRock Biotherapeutics
  • 12.43 Numab
  • 12.44 OPKO Health
  • 12.45 Pfizer
  • 12.46 Regeneron Pharmaceuticals
  • 12.47 Revitope
  • 12.48 Roche
  • 12.49 Sanofi
  • 12.50 Sichuan Baili Pharmaceutical
  • 12.51 SystImmune
  • 12.52 Virtuoso Therapeutics
  • 12.53 Xencor
  • 12.54 Y-Biologics
  • 12.55 Zymeworks